It was harder to envision 10 when we were at 2. But , if you recall there was a great deal of grousing about every downward swing even if it was in a wide trading band as Illverson might have pointed out. There was considerable uncertainty inherent in the stock during most of that period.
Previous periods of apparent success in the past turned in massive downswings because the they were over hyped and over bought - including the partnership with Merck considering the time framed that was needed for Rida's development. Not the case here. Ariad is now under owned considering the prospects. Institutional ownership is still light by comparison to the future outlook. The certainty of success has never been clearer and it is that which make's it "easy money" at this price. The gain might be only 60 to 100% by comparison but the risk is out of the stock and if another molecule pops out of the pipeline next year, all bets are off about the top on this stock.
News 
Market Data 
Discover 
